Acorn Capital Advisors’s UroGen Pharma URGN Stock Holding History

Acorn Capital Advisors’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$61.6M	Hold	1,673,420	–	–	16.8%	2
2026 Q1	$30.1M	Buy	1,673,420 +225,000	+16%	+$4.51M	8.55%	3
2025 Q4	$33.9M	Buy	1,448,420 +188,671	+15%	+$4.09M	11.49%	3
2025 Q3	$25.1M	Hold	1,259,749	–	–	12.76%	2
2025 Q2	$17.3M	Sell	1,259,749 -256,554	-17%	-$2.46M	11.29%	2
2025 Q1	$16.8M	Hold	1,516,303	–	–	11.18%	2
2024 Q4	$16.1M	Buy	+1,516,303	New	+$18.2M	8.69%	4

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Acorn Capital Advisors's URGN Position: Q2 2026 in Review

Acorn Capital Advisors held its UroGen Pharma (URGN) position steady in Q2 2026 at 1,673,420 shares worth $61.6M. The position accounts for 16.8% of the portfolio, ranked #2.

Acorn Capital Advisors first reported a position in URGN in Q4 2024 and has held it in 7 quarters since. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Acorn Capital Advisors held 1,673,420 shares of UroGen Pharma worth $61.6M as of Q2 2026.
Acorn Capital Advisors left its UroGen Pharma share count unchanged in Q2 2026.
UroGen Pharma made up 16.8% of Acorn Capital Advisors's portfolio in Q2 2026, its #2 holding.
Acorn Capital Advisors first reported a position in UroGen Pharma in Q4 2024 and has held it in 7 quarters since.
190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Acorn Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.